{"mainPropery":{"diseaseId":10614,"diseaseName":"Adrenomyeloneuropathy","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/10614/adrenomyeloneuropathy","synonyms":["AMN"],"synonyms-with-source":[{"name":"AMN"}],"identifiers":[{"identifierType":"OMIM","identifierId":"300100"},{"identifierType":"ORPHANET","identifierId":"139399"},{"identifierType":"UMLS","identifierId":"C1527231"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":8,"diseaseTypeName":"Endocrine Diseases","source":"Orphanet"},{"diseaseTypeId":24,"diseaseTypeName":"Male Reproductive Diseases"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":195,"resourceName":"United Leukodystrophy Foundation","abbreviation":"ULF","address1":"224 North Second Street","address2":"Suite 2","address3":"","address4":"","address5":"","city":"DeKalb","state":"IL","zip":"60115 ","country":"United States","phone":"+1-815-748-3211 ","tty":"","tollFree":"1-800-728-5483","fax":"+1-815-748-0844","email":"office@ulf.org","url":"https://ulf.org/","freeText":""},{"resourceID":348,"resourceName":"The Adrenoleukodystrophy Foundation","abbreviation":"","address1":"241 Camden Street","address2":"","address3":"","address4":"","address5":"","city":"Slidell","state":"LA","zip":"70461","country":"United States","phone":"985-718-4728 ","tty":"","tollFree":"","fax":"","email":"info@aldfoundation.org","url":"http://www.aldfoundation.org","freeText":""},{"resourceID":350,"resourceName":"The Myelin Project","abbreviation":"","address1":"P.O. Box 39","address2":"","address3":"","address4":"","address5":"","city":"Pacific Palisades","state":"CA","zip":"90272","country":"United States","phone":"800-869-3546; 806 356 4693","tty":"","tollFree":"","fax":"806 356 4694  ","email":"info@myelin.org","url":"http://www.myelin.org","freeText":""},{"resourceID":422,"resourceName":"Association Europ√©enne contre les Leucodystrophies (ELA)","abbreviation":"","address1":"European Leukodystrophy Association","address2":"2, rue Mi-les-Vignes","address3":"BP 61024","address4":"","address5":"","city":"54521 Laxou Cedex","state":"","zip":"","country":"France","phone":"333 83 30 93 34 ","tty":"","tollFree":"","fax":"333 83 30 00 68 ","email":"ela@ela-asso.com","url":"http://www.ela-asso.com","freeText":""},{"resourceID":2219,"resourceName":"Alex The Leukodystrophy Charity","abbreviation":"Alex TLC","address1":"45 Peckham High Street","address2":"","address3":"","address4":"","address5":"","city":"London","state":"","zip":"SE15 5EB","country":"United Kingdom","phone":" 020 7701 4388","tty":"","tollFree":"","fax":"","email":"info@alextlc.org","url":"https://www.alextlc.org","freeText":""},{"resourceID":3540,"resourceName":"ALD Connect","abbreviation":"","address1":"c/o Kailey Walsh","address2":"Massachusetts General Hospital","address3":"175 Cambridge Street","address4":"Suite 340","address5":"","city":"Boston","state":"MA","zip":"02114","country":"United States","phone":"","tty":"","tollFree":"","fax":"","email":"info@aldconnect.org","url":"http://aldconnect.org/","freeText":""},{"resourceID":3850,"resourceName":"National Adrenal Diseases Foundation","abbreviation":"NADF","address1":"P.O. Box 566","address2":"","address3":"","address4":"","address5":"","city":"Lake Zurich","state":"IL","zip":"60047","country":"","phone":"+1-(847) 726-9010","tty":"","tollFree":"","fax":"","email":"nadfmail@nadf.us","url":"https://www.nadf.us","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/300100' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=%22adrenomyeloneuropathy%22%5Btitle/abstract%5D%20AND%20hasabstract%5Btext%5D&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Adrenomyeloneuropathy. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Adrenomyeloneuropathy%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Adrenomyeloneuropathy. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/x-linked-adrenoleukodystrophy' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Adrenomyeloneuropathy. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":585,"resourceId":1323,"resourceName":"United Leukodystrophy Foundation","descriptionText":"The <a href='http://ulf.org/adrenomyeloneuropathy-amn' target='_blank'>United Leukodystrophy Foundation</a> has developed an information page on Adrenomyeloneuropathy. Click on the link above to view this information page.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0162309/' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/43/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/001182.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1177387-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=139399' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=x-ald' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:300100' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":8376,"questionText":"What is adrenomyeloneuropathy?","answerText":"<strong>Adrenomyeloneuropathy (AMN)</strong> is an inherited condition that affects the spinal cord. It is a form of <a href=\"http://rarediseases.info.nih.gov/gard/5758/x-linked-adrenoleukodystrophy/resources/1\" target=\"_blank\">X-linked adrenoleukodystrophy</a>. On average, people with AMN begin to develop&nbsp;features in the late&nbsp;twenties. Signs and symptoms may include progressive stiffness and weakness of the legs; <a href=\"http://www.mayoclinic.org/diseases-conditions/ataxia/basics/definition/con-20030428\" target=\"_blank\">ataxia</a>; speech difficulties; <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000378.htm\" target=\"_blank\">adrenal insufficiency</a>; sexual dysfunction; and bladder control issues. Some people with AMN also have brain involvement which can lead to behavioral abnormalities, vision loss, hearing problems, and/or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003200.htm\" target=\"_blank\">seizures</a>.[8397][8399] AMN is caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in the <a href=\"http://ghr.nlm.nih.gov/gene/ABCD1\" target=\"_blank\"><em>ABCD1</em></a> gene and is inherited in an <a href=\"http://www.genome.gov/Glossary/index.cfm?id=209\" target=\"_blank\">X-linked</a> manner.[8398][8403] Treatment addresses the symptoms in each person and may include <a href=\"http://www.nlm.nih.gov/medlineplus/steroids.html\" target=\"_blank\">steroid replacement therapy</a> for adrenal insufficiency.[8399][8403]","dateModified":"2015-02-26T15:15:00"},"basicQuestions":[{"questionId":8369,"questionText":"What are the signs and symptoms of adrenomyeloneuropathy?","answerText":"Adrenomyeloneuropathy (AMN) is a form of <a href=\"http://rarediseases.info.nih.gov/gard/5758/x-linked-adrenoleukodystrophy/resources/1\" target=\"_blank\">X-linked adrenoleukodystrophy</a>. On average, people with AMN begin to develop symptoms at age 28; however, the age of onset can range from the second to the fifth decade of life. There are two forms of AMN that vary in severity. The milder form of the condition (AMN without cerebral involvement) only affects the spinal cord, while the more severe form (AMN with cerebral involvement) affects both the brain and the spinal cord.[8397]<br />\r\n<br />\r\nSigns and symptoms of AMN vary, but may include:[8397][8399][8398]\r\n<ul>\r\n    <li>Difficulty walking</li>\r\n    <li>Changes in gait (style of walking)</li>\r\n    <li>Progressive stiffness and weakness of the legs</li>\r\n    <li><a href=\"http://www.mayoclinic.org/diseases-conditions/ataxia/basics/definition/con-20030428\" target=\"_blank\">Ataxia</a></li>\r\n    <li><a href=\"http://www.ninds.nih.gov/disorders/hypertonia/hypertonia.htm\" target=\"_blank\">Hypertonia</a></li>\r\n    <li>Speech difficulties</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000378.htm\" target=\"_blank\">Adrenal insufficiency</a></li>\r\n    <li>Sexual dysfunction and/or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003164.htm\" target=\"_blank\">impotence</a></li>\r\n    <li>Problems with bladder control</li>\r\n    <li>Mild <a href=\"http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm\" target=\"_blank\">peripheral neuropathy</a></li>\r\n    <li>Weight loss</li>\r\n    <li>Nausea</li>\r\n</ul>\r\nIn addition to the symptoms above, people with AMN with cerebral involvement may develop behavioral abnormalities, vision loss, hearing problems and/or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003200.htm\" target=\"_blank\">seizures</a>.[8399]","dateModified":"2015-02-25T10:40:00","resourceClassificationName":"Symptoms","references":[{"referenceId":8397,"authors":"","articleTitle":"Adrenomyeloneuropathy (AMN)","bookWebsiteJournalTitle":"United Leukodystrophy Foundation","date":"","volume":"","pages":"","url":"http://ulf.org/adrenomyeloneuropathy-amn","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8398,"authors":"","articleTitle":"X-linked adrenoleukodystrophy","bookWebsiteJournalTitle":"Genetics Home Reference","date":"July 2013","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/x-linked-adrenoleukodystrophy","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8399,"authors":"Alan K Percy, MD; Ronald JA Wanders, PhD","articleTitle":"Adrenoleukodystrophy","bookWebsiteJournalTitle":"UpToDate","date":"February 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8371,"questionText":"What causes adrenomyeloneuropathy?","answerText":"Adrenomyeloneuropathy (AMN) is caused by changes (<a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>) in the <a href=\"http://ghr.nlm.nih.gov/gene/ABCD1\" target=\"_blank\"><em>ABCD1</em></a> gene. This gene gives the body instructions to make the adrenoleukodystrophy protein (ALDP) which helps transport certain types of fats (called very long-chain fatty acids) into the <a href=\"http://ghr.nlm.nih.gov/glossary=peroxisomes\" target=\"_blank\">peroxisomes</a>. Peroxisomes are structures in cells that contain <a href=\"http://www.genome.gov/Glossary/index.cfm?id=58\" target=\"_blank\">enzymes</a>&nbsp;used to&nbsp;help break down fats and other substances. Mutations in the <em>ABCD1</em> gene cause low levels of functional ALDP, which then causes high levels of very long-chain fatty acids to build up in the body. High levels of these fats in the nervous system, adrenal glands, and testes disrupt their normal function, resulting in the features of AMN.[8398]","dateModified":"2015-02-25T15:23:00","resourceClassificationName":"Cause","references":[{"referenceId":8398,"authors":"","articleTitle":"X-linked adrenoleukodystrophy","bookWebsiteJournalTitle":"Genetics Home Reference","date":"July 2013","volume":"","pages":"","url":"http://ghr.nlm.nih.gov/condition/x-linked-adrenoleukodystrophy","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8372,"questionText":"How is adrenomyeloneuropathy inherited?","answerText":"Adrenomyeloneuropathy (AMN) is inherited in an <a href=\"http://www.genome.gov/Glossary/index.cfm?id=209\" target=\"_blank\">X-linked</a> manner.[8403] A condition is considered X-linked if the responsible gene is located on the <a href=\"http://ghr.nlm.nih.gov/chromosome/X\" target=\"_blank\">X chromosome</a>, one of the two sex chromosomes. The <a href=\"http://ghr.nlm.nih.gov/chromosome/Y\" target=\"_blank\">Y chromosome </a>is the other sex chromosome. Women have two X chromosomes and men have an X and a Y chromosome.<br />\r\n<br />\r\nBecause men have one copy of the X chromosome, a <a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=\"_blank\">mutated</a> copy of the responsible <a href=\"http://www.genome.gov/Glossary/index.cfm?id=70\" target=\"_blank\">gene</a> in each cell is enough to cause signs or symptoms of the condition. A man with an X-linked condition will pass the mutation to all of his daughters and none of his sons. <br />\r\n<br />\r\nBecause women have two X chromosomes, the effect of the mutation may be masked by the other, normal copy of the gene, on the other X chromosome. Women with one mutation are often referred to as \"<a href=\"http://www.genome.gov/Glossary/index.cfm?id=23\" target=\"_blank\">carriers</a>\" of an X-linked condition. In most cases, carrier women have no symptoms  or are mildly affected. However, some may be just as severely affected as males with the condition. Women who carry an X-linked condition have a 50% chance of passing the mutation on with each pregnancy. <br />\r\n<br />\r\nIn AMN approximately 20% of women who carry one <a href=\"http://ghr.nlm.nih.gov/gene/ABCD1\" target=\"_blank\"><em>ABCD1</em></a> mutation will develop progressive stiffness and weakness in their legs, often in middle age or later. These women typically have normal adrenal function.[8403]","dateModified":"2015-02-25T15:35:00","resourceClassificationName":"Inheritance","references":[{"referenceId":8403,"authors":"Steven J Steinberg, PhD, Ann B Moser, BA, and Gerald V Raymond, MD","articleTitle":"X-Linked Adrenoleukodystrophy","bookWebsiteJournalTitle":"GeneReviews","date":"April 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1315/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8373,"questionText":"How is adrenomyeloneuropathy diagnosed?","answerText":"A diagnosis of adrenomyeloneuropathy (AMN) is typically suspected based on the presence of characteristic signs and symptoms. A blood test that measures the levels of a specific type of fat (very long-chain fatty acids) and/or genetic testing for a mutation in the <a href=\"http://ghr.nlm.nih.gov/gene/ABCD1\" target=\"_blank\"><em>ABCD1</em></a> gene can be used to confirm the diagnosis. Once a diagnosis is made, an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003791.htm\" target=\"_blank\">MRI of the brain</a> may be recommended to determine if the person has AMN with cerebral involvement (brain and spinal cord affected) or AMN without cerebral involvement (only spinal cord affected).[8403][8397][8399]","dateModified":"2015-02-26T10:08:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":8397,"authors":"","articleTitle":"Adrenomyeloneuropathy (AMN)","bookWebsiteJournalTitle":"United Leukodystrophy Foundation","date":"","volume":"","pages":"","url":"http://ulf.org/adrenomyeloneuropathy-amn","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8399,"authors":"Alan K Percy, MD; Ronald JA Wanders, PhD","articleTitle":"Adrenoleukodystrophy","bookWebsiteJournalTitle":"UpToDate","date":"February 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8403,"authors":"Steven J Steinberg, PhD, Ann B Moser, BA, and Gerald V Raymond, MD","articleTitle":"X-Linked Adrenoleukodystrophy","bookWebsiteJournalTitle":"GeneReviews","date":"April 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1315/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8374,"questionText":"How is adrenomyeloneuropathy treated?","answerText":"Treatment of adrenomyeloneuropathy (AMN) varies based on the signs and symptoms  in each person. For example, <a href=\"http://www.nlm.nih.gov/medlineplus/steroids.html\" target=\"_blank\">steroid replacement therapy</a> may be prescribed in people with <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000378.htm\" target=\"_blank\">adrenal insufficiency</a>. Physical therapy may also be recommended to help build and maintain muscle strength.[8397][8399][8403]","dateModified":"2015-02-26T10:46:00","resourceClassificationName":"Treatment","references":[{"referenceId":8397,"authors":"","articleTitle":"Adrenomyeloneuropathy (AMN)","bookWebsiteJournalTitle":"United Leukodystrophy Foundation","date":"","volume":"","pages":"","url":"http://ulf.org/adrenomyeloneuropathy-amn","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8399,"authors":"Alan K Percy, MD; Ronald JA Wanders, PhD","articleTitle":"Adrenoleukodystrophy","bookWebsiteJournalTitle":"UpToDate","date":"February 2015","volume":"","pages":"","url":"","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8403,"authors":"Steven J Steinberg, PhD, Ann B Moser, BA, and Gerald V Raymond, MD","articleTitle":"X-Linked Adrenoleukodystrophy","bookWebsiteJournalTitle":"GeneReviews","date":"April 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1315/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":8375,"questionText":"What is the long-term outlook for people with adrenomyeloneuropathy?","answerText":"The long-term outlook (prognosis) for people with adrenomyeloneuropathy (AMN) varies depending on the subtype. In general, AMN with cerebral involvement (both brain and spinal cord affected) has a worse prognosis than AMN without cerebral involvement (only spinal cord affected). Many people without cerebral involvement are able to maintain successful personal and professional lives with physical therapy, management of bladder control issues, and counseling.[8397][8403]<br />\r\n<br />\r\nApproximately 40-45% of people affected by AMN show some degree of brain involvement on <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003791.htm\" target=\"_blank\">MRI</a>. In some of these cases (around 10-20%), the brain involvement becomes severely progressive (worsening over time) and may lead to cognitive decline, behavioral abnormalities, physical disability, or even death.[8397][8403]","dateModified":"2015-02-26T14:57:00","resourceClassificationName":"Prognosis","references":[{"referenceId":8397,"authors":"","articleTitle":"Adrenomyeloneuropathy (AMN)","bookWebsiteJournalTitle":"United Leukodystrophy Foundation","date":"","volume":"","pages":"","url":"http://ulf.org/adrenomyeloneuropathy-amn","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":8403,"authors":"Steven J Steinberg, PhD, Ann B Moser, BA, and Gerald V Raymond, MD","articleTitle":"X-Linked Adrenoleukodystrophy","bookWebsiteJournalTitle":"GeneReviews","date":"April 2012","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1315/","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":6895,"relatedDiseaseName":"Leukodystrophy","relation":"Parent","isRare":true,"hasGardPage":true},{"relatedDiseaseId":5758,"relatedDiseaseName":"X-linked adrenoleukodystrophy ","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":14295,"phenoTypeName":"Abnormality of the cerebral white matter","percentRanges":"-"},{"phenoTypeId":4756,"phenoTypeName":"Alopecia","percentRanges":"-"},{"phenoTypeId":4486,"phenoTypeName":"Attention deficit hyperactivity disorder","percentRanges":"-"},{"phenoTypeId":10089,"phenoTypeName":"Blindness","percentRanges":"-"},{"phenoTypeId":13777,"phenoTypeName":"Bowel incontinence","percentRanges":"-"},{"phenoTypeId":9377,"phenoTypeName":"Bulbar palsy","percentRanges":"-"},{"phenoTypeId":6020,"phenoTypeName":"Dementia","percentRanges":"-"},{"phenoTypeId":13573,"phenoTypeName":"Elevated circulating long chain fatty acid concentration","percentRanges":"-"},{"phenoTypeId":11303,"phenoTypeName":"Hearing impairment","percentRanges":"-"},{"phenoTypeId":10277,"phenoTypeName":"Hyperpigmentation of the skin","percentRanges":"-"},{"phenoTypeId":9728,"phenoTypeName":"Hypogonadism","percentRanges":"-"},{"phenoTypeId":1623,"phenoTypeName":"Impaired vibration sensation at ankles","percentRanges":"-"},{"phenoTypeId":14170,"phenoTypeName":"Impotence","percentRanges":"-"},{"phenoTypeId":11393,"phenoTypeName":"Incoordination","percentRanges":"-"},{"phenoTypeId":13459,"phenoTypeName":"Limb ataxia","percentRanges":"-"},{"phenoTypeId":6355,"phenoTypeName":"Loss of speech","percentRanges":"-"},{"phenoTypeId":13670,"phenoTypeName":"Lower limb muscle weakness","percentRanges":"-"},{"phenoTypeId":13851,"phenoTypeName":"Neurodegeneration","percentRanges":"-"},{"phenoTypeId":5159,"phenoTypeName":"Paraparesis","percentRanges":"-"},{"phenoTypeId":8730,"phenoTypeName":"Polyneuropathy","percentRanges":"-"},{"phenoTypeId":1381,"phenoTypeName":"Primary adrenal insufficiency","percentRanges":"-"},{"phenoTypeId":5255,"phenoTypeName":"Progressive","percentRanges":"-"},{"phenoTypeId":6006,"phenoTypeName":"Psychosis","percentRanges":"-"},{"phenoTypeId":8719,"phenoTypeName":"Seizure","percentRanges":"-"},{"phenoTypeId":5658,"phenoTypeName":"Slurred speech","percentRanges":"-"},{"phenoTypeId":8712,"phenoTypeName":"Spastic paraplegia","percentRanges":"-"},{"phenoTypeId":13711,"phenoTypeName":"Truncal ataxia","percentRanges":"-"},{"phenoTypeId":7928,"phenoTypeName":"Urinary bladder sphincter dysfunction","percentRanges":"-"},{"phenoTypeId":6356,"phenoTypeName":"Urinary incontinence","percentRanges":"-"},{"phenoTypeId":9162,"phenoTypeName":"Visual loss","percentRanges":"-"},{"phenoTypeId":5707,"phenoTypeName":"X-linked recessive inheritance","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Adrenomyeloneuropathy"}